Chattem former exec George Davy
In arbitration with his former employer. Davy has requested "compensation, damages, benefits and certain expenses arising" from his contract, according to Chattem's 1989 annual report. Davy joined Chattem in late 1987 as chief operating officer, a newly-created position between Chairman Alex Guerry and Exec VP Zan Guerry and other managers. The experiment in bringing an outsider to the family-controlled business was short-lived. Davy left at the end of 1988.
You may also be interested in...
A Senate Health Committee update hearing on the COVID-19 federal response was noteworthy primarily for demonstrating that FDA Commissioner Stephen Hahn appears to have salvaged the agency’s position as a voice of credibility with a key political constituency – at least for now.
The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.
The documents issued by the US agency on 29 September set slightly different accuracy standards, reflecting the increased fragility of hospital patients.